Factor VII Antibody (AHVII-5031): sc-73460

Factor VII Antibody (AHVII-5031) is a mouse monoclonal IgG1 antibody that detects Factor VII in human samples through western blotting (WB). Factor VII, also known as serum prothrombin conversion accelerator, proconvertin, or coagulation factor 7, is a crucial component in the hemostatic process, playing a vital role in the blood coagulation cascade. This 406 amino acid protein is synthesized in the liver and circulates as an inactive precursor until activated by proteolytic cleavage, which occurs at the Arg 152-Ile 153 site, resulting in the formation of Factor VII A. The active form of Factor VII is a serine protease that consists of a heavy chain linked by disulfide bonds to a light chain, featuring two epidermal growth factor-like domains essential for function. Proper functioning of Factor VII is critical for fibrin clot formation and platelet aggregation promotion, necessary for effective hemostasis following tissue injury. Deficiencies in Factor VII, often due to mutations at the F7 locus, can lead to bleeding disorders, although many individuals remain asymptomatic or exhibit mild symptoms. Anti-Factor VII antibody (AHVII-5031) is an invaluable tool for researchers studying coagulation pathways and related disorders, providing insights into hemostasis mechanisms and potential therapeutic targets.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Factor VII Antibody (AHVII-5031) References:

1. Factor VII levels in patients undergoing coronary angiography: factor VII and coronary artery disease.  |  Domaniç, N., et al. 2001. J Cardiovasc Risk. 8: 57-61. PMID: 11324371
2. Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.  |  Morishita, E., et al. 2002. J Atheroscler Thromb. 9: 72-7. PMID: 12238641
3. A comparison between recombinant activated factor VII (Aryoseven) and Novoseven in patients with congenital factor VII deficiency.  |  Faranoush, M., et al. 2015. Clin Appl Thromb Hemost. 21: 724-8. PMID: 24651301
4. Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII.  |  Broze, GJ., et al. 1985. J Clin Invest. 76: 937-46. PMID: 2995451
5. Intrapulmonary Activated Factor VII for Hemoptysis Complicating Pulmonary Thromboendarterectomy.  |  Ansari, A., et al. 2020. Ann Thorac Surg. 109: e243-e245. PMID: 31470015
6. Association Between R353Q (rs6046) Polymorphism in Factor VII with Coronary Heart Disease.  |  Li, F., et al. 2020. Int Heart J. 61: 641-650. PMID: 32684587
7. The immunodepletion of factor VII from human plasma using a monoclonal antibody.  |  Cerskus, AL., et al. 1985. Br J Haematol. 61: 467-75. PMID: 3904814
8. Isolation and characterization of human factor VII. Activation of factor VII by factor Xa.  |  Bajaj, SP., et al. 1981. J Biol Chem. 256: 253-9. PMID: 6778860
9. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma.  |  Bernardi, F., et al. 1996. Arterioscler Thromb Vasc Biol. 16: 72-6. PMID: 8548429
10. Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates.  |  Hellstern, P., et al. 1997. Thromb Res. 86: 493-504. PMID: 9219329

The preferred Factor VII antibody is Factor VII Antibody (CaFVII-22): sc-101369.